RHEA Generics completed the final leg of its nationwide Trade Launch series on June 5 at Acacia Hotel Davao, bringing together its global pharmaceutical partners, business leaders, and key stakeholders in a milestone event that capped a four-part regional rollout across the country.
The Mindanao launch marked the culmination of a campaign that introduced RHEA Generics’ growing portfolio and reaffirmed its commitment to making world-class quality medicines more accessible to Filipino families.
The event was attended by members of Mercury Drug’s leadership team, along with the District Managers and Branch Managers of the Mindanao region.
Since its establishment in 2014, RHEA Generics has introduced a business model that brought a fresh approach to the local pharmaceutical landscape. RHEA Generics offers generic counterparts sourced from global pharmaceutical companies that pioneered the development and commercialization of the patented molecules worldwide. Through this model, Filipino patients gain access to medicines manufactured to the same quality standards as their branded counterparts, while benefiting from more affordable pricing.
The initiative was first launched through a partnership with Pfizer, paving the way for collaborations with other leading pharmaceutical companies, including Viatris, Sanofi, GSK, Otsuka, Merck, Fresenius Kabi, AstraZeneca, Lundbeck, OEP Philippines, Boehringer Ingelheim, Bayer, Sandoz, and Menarini.
What began with an initial portfolio of five products has since expanded to 25 generic medicines, reflecting the continued confidence of global pharmaceutical partners in RHEA Generics’ mission of broadening access to quality healthcare.
A key distinguishing feature of RHEA Generics is that its products are manufactured in the same facilities where the innovator brands of its partner pharmaceutical companies are produced. This allows patients to access medicines that offer the same efficacy, quality, and safety standards associated with the original brands, while remaining within reach of more Filipino households.
Beyond affordability, the company has strengthened access to treatment by leveraging Mercury Drug’s extensive nationwide network, making these medicines available to communities across the country.
Over the years, RHEA Generics has helped address treatment needs for some of the most common health conditions affecting Filipinos, including hypertension, diabetes, heart disease, asthma, respiratory infections, kidney infections, thyroid disorders, sexually transmitted diseases, gout, epilepsy, skin and ear infections, dental infections, psychological disorders, and pain management.
As shared by Giezel Jane Sarmiento, Marketing Head of the Pharma Business Unit and RHEA Generics’ Brand Manager since its inception, “The biggest lesson for us is that affordability should never come at the expense of trust. Filipino patients want medicines they can afford, but more importantly, they want medicines they can believe in. “Through RHEA Generics, we’ve learned that when you combine world-class pharmaceutical partners, nationwide accessibility through Mercury Drug, and a genuine commitment to patients—quality, affordability, and accessibility can coexist. It’s not about asking patients to compromise, it’s about giving them the confidence that they don’t have to.”
The completion of the Trade Launch series in Mindanao represents more than the conclusion of a nationwide campaign. It reflects more than a decade of collaboration between RHEA Generics, Mercury Drug, and its global pharmaceutical partners, united by a shared goal of making trusted, world-class quality medicines more attainable for Filipino patients.
As RHEA Generics continues to expand its portfolio and strengthen partnerships across the healthcare sector, it remains focused on helping more Filipinos gain access to world-class treatment options that support healthier lives.
